About The Study: In this randomized clinical trial of 3,777 patients with ST-segment elevation myocardial infarction (STEMI; a type of heart attack), the Chinese patent medicine Tongxinluo, as an adjunctive therapy in addition to STEMI guideline-directed treatments, significantly improved both 30-day and 1-year clinical outcomes. Further research is needed to determine the mechanism of action of Tongxinluo in STEMI.
Authors: Yuejin Yang, M.D., Ph.D., and Runlin Gao, M.D., of the Chinese Academy of Medical Sciences and Peking Union Medical College in Beijing, are the corresponding authors.
To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/
Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.
# # #
Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2023.19524?guestAccessKey=66aee3a0-78fc-415c-846c-56ca5356da82&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=102423